Skip to main
A plain-English orientation to the most-studied research peptides across tissue repair, the growth-hormone axis, metabolic, longevity, immune and cognitive research — what each one is, how it works, and what the literature actually shows.
Peptides National

PAPERS / CHECK THE FINDINGS

Which twenty-one sources can answer your study questions?

A claim about hunger or healing needs evidence you can check. These papers include patient trials, reviews of earlier papers, animal tests, and cells grown in dishes.

What do the paper numbers and study labels mean?

Match the small number beside a claim to the paper below. Tirzepatide uses 1–7, semaglutide 8–11, Thymosin Alpha-1 12–16, and BPC-157 17–21. Original titles accompany a link to each paper.

A number guides you like a newspaper's page number.

A review examines earlier papers. The reviewers aren't treating new patients. A systematic review searches for papers using stated rules.

A meta-analysis combines their results to judge the overall difference. A narrative review describes papers without that combined calculation.

Efficacy asks whether treatment helped. Clinical work involves people. Controlled trials compare treatments.

A pilot study starts with a small group to see what happens. For your questions, read each peptide’s findings about patients and remaining doubts.

  1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. ↗
  2. Farzam K, Patel P. Tirzepatide (StatPearls). StatPearls [Internet], NCBI Bookshelf. 2024. ↗
  3. Zeng Q, et al. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023. ↗
  4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. ↗
  5. Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021. ↗
  6. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020. ↗
  7. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018. ↗
  8. Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. ↗
  9. Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. ↗
  10. Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. ↗
  11. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. ↗
  12. Wu J, Pei F, Zhou L, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025. ↗
  13. Dominari A, Hathaway Iii D, Pandav K, et al. Thymosin alpha 1: A comprehensive review of the literature. World J Virol. 2020. ↗
  14. Liu Y, Pan Y, Hu Z, et al. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis. 2020. ↗
  15. Costantini C, Bellet MM, Pariano M, et al. A Reappraisal of Thymosin Alpha1 in Cancer Therapy. Front Oncol. 2019. ↗
  16. Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013. ↗
  17. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  18. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  19. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  20. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  21. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10:1032-1037. ↗